Literature DB >> 28792011

F-36316 A and B, novel vasoactive compounds, isolated from Incrucipulum sp. SANK 10414.

Yuki Hirota-Takahata1, Yoko Ishimoto2, Emi Kurosawa1, Yuko Iwadate1, Yoshiko Onozawa2, Isshin Tanaka1, Masahiro Tanaka1, Hideki Kobayashi2.   

Abstract

In the course of our screening program for vasoactive compounds using co-culture assay of endothelial cells and fibroblast cells, potent activity was detected in the cultured broth of Incrucipulum sp. SANK 10414. Two active compounds, F-36316 A and B, and a non-active homolog, F-36316 C, were isolated from the broth. The structures of F-36316 A, B and C were elucidated by physicochemical data and spectral analyses, and found to be new 3-acylated tetronic acid homologs. F-36316 A and B induced morphological changes of endothelial cells different from vascular endothelial growth factor (VEGF) or vestaines in the assay with EC50 values of 1.8 and 11.7 μM, respectively. Furthermore, F-36316 A and B suppressed VEGF-induced vascular permeability induction in mice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28792011     DOI: 10.1038/ja.2017.84

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  22 in total

1.  Design and synthesis of a dimeric derivative of RK-682 with increased inhibitory activity against VHR, a dual-specificity ERK phosphatase: implications for the molecular mechanism of the inhibition.

Authors:  T Usui; S Kojima; S Kidokoro; K Ueda; H Osada; M Sodeoka
Journal:  Chem Biol       Date:  2001-12

Review 2.  Moyamoya disease: a review of histopathology, biochemistry, and genetics.

Authors:  David G Weinberg; Omar M Arnaout; Rudy J Rahme; Salah G Aoun; H Hunt Batjer; Bernard R Bendok
Journal:  Neurosurg Focus       Date:  2011-06       Impact factor: 4.047

3.  Lowdenic acid: a new antifungal polyketide-derived metabolite from a new fungicolous Verticillium sp.

Authors:  Rihab F Angawi; Dale C Swenson; James B Gloer; Donald T Wicklow
Journal:  J Nat Prod       Date:  2003-09       Impact factor: 4.050

4.  Focused library with a core structure extracted from natural products and modified: application to phosphatase inhibitors and several biochemical findings.

Authors:  Go Hirai; Mikiko Sodeoka
Journal:  Acc Chem Res       Date:  2015-04-20       Impact factor: 22.384

5.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Authors:  Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3.

Authors:  T Kimura; T Watanabe; K Sato; J Kon; H Tomura; K Tamama; A Kuwabara; T Kanda; I Kobayashi; H Ohta; M Ui; F Okajima
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 7.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 8.  Vascular endothelial growth factors and vascular permeability.

Authors:  David O Bates
Journal:  Cardiovasc Res       Date:  2010-04-16       Impact factor: 10.787

9.  Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.

Authors:  Shom Goel; Nisha Gupta; Brian P Walcott; Matija Snuderl; Cristina T Kesler; Nathaniel D Kirkpatrick; Takahiro Heishi; Yuhui Huang; John D Martin; Eleanor Ager; Rekha Samuel; Shuhan Wang; John Yazbek; Benjamin J Vakoc; Randall T Peterson; Timothy P Padera; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2013-07-30       Impact factor: 13.506

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.